Ignite Creation Date:
2024-05-05 @ 4:51 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00321750
Status:
TERMINATED
Last Update Posted:
2006-10-18
First Post:
2006-05-02
Brief Title:
Treatment of Oral Erosive Lichen Planus With Pimecrolimus Cream
Sponsor:
Centre Hospitalier Universitaire de Nice
Organization:
Centre Hospitalier Universitaire de Nice
Study Overview
Official Title:
Phase 2 Study of the Treatment of Oral Erosive Lichen Planus With 1 Pimecrolimus Cream a Double Blind Randomized Prospective Trial With Measurement of Pimecrolimus Levels in the Blood
Status:
TERMINATED
Status Verified Date:
2006-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Background and hypothesis Oral erosive lichen planus OELP is a severe form of mucosal lichen planus Lesions often induce intense pain and limit feeding Its course is chronic with flares and spontaneous remissions are rare Treatment is difficult topical steroids are usually used first but antimalarials oral retinoids systemic steroids immunosuppressive drugs and even extracorporeal photochemotherapy can be necessary for treating severe forms The need for novel therapies with less morbidity is obvious Calcineurin inhibitors have a theoretical interest in treating OELP this has been emphasized by several open studies performed with topical tacrolimus The effectiveness of 1 pimecrolimus cream has been suggested by a few case reports and by one recent comparative study which confirmed the potential interest of topical pimecrolimus in treating OELP The absorption of pimecrolimus through human mucosa is still unknown Its application on ulcerative lesions such as OELP ones could lead to significant systemic levels of the molecule
Objective To evaluate the efficacy of 1 pimecrolimus cream in treating oral erosive lichen planus OELP and to assess its tolerance
Objective To evaluate the efficacy of 1 pimecrolimus cream in treating oral erosive lichen planus OELP and to assess its tolerance
Detailed Description:
Background and hypothesis Oral erosive lichen planus OELP is a severe form of mucosal lichen planus Lesions often induce intense pain and limit feeding Its course is chronic with flares and spontaneous remissions are rare Treatment is difficult topical steroids are usually used first but antimalarials oral retinoids systemic steroids immunosuppressive drugs and even extracorporeal photochemotherapy can be necessary for treating severe forms The need for novel therapies with less morbidity is obvious Calcineurin inhibitors have a theoretical interest in treating OELP this has been emphasized by several open studies performed with topical tacrolimus The effectiveness of 1 pimecrolimus cream has been suggested by a few case reports and by one recent comparative study which confirmed the potential interest of topical pimecrolimus in treating OELP The absorption of pimecrolimus through human mucosa is still unknown Its application on ulcerative lesions such as OELP ones could lead to significant systemic levels of the molecule
Objective To evaluate the efficacy of 1 pimecrolimus cream in treating oral erosive lichen planus OELP and to assess its tolerance
Design Double blind randomized trial with placebo control
Settings Outpatients of the Department of Dermatology of the University hospital of Nice France
Patients Fourteen consecutive patients with OELP confirmed by histological examination and with a clinical score superior to 3 1 pimecrolimus cream or its vehicle were applied on ulcerated lesions twice a day for 4 weeks
Main outcome measures the efficacy of the treatment was quantified using a 12 points clinical score Blood level of pimecrolimus was analyzed at D0 D14 and D28
Objective To evaluate the efficacy of 1 pimecrolimus cream in treating oral erosive lichen planus OELP and to assess its tolerance
Design Double blind randomized trial with placebo control
Settings Outpatients of the Department of Dermatology of the University hospital of Nice France
Patients Fourteen consecutive patients with OELP confirmed by histological examination and with a clinical score superior to 3 1 pimecrolimus cream or its vehicle were applied on ulcerated lesions twice a day for 4 weeks
Main outcome measures the efficacy of the treatment was quantified using a 12 points clinical score Blood level of pimecrolimus was analyzed at D0 D14 and D28
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None